

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

January 16, 2007

David Saliwanchik

David R. Saliwanchik, Patent Attorney

RESPONSE UNDER 37 CFR 1.111
Examining Group 1617
Patent Application
Docket No. GJE-6757C1
Serial No. 10/617,847

RECEIVED
CENTRAL FAX CENTER

JAN 16 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Layla Soroush
Art Unit : 1617
Applicant : Hazel Judith Bardsley *et al.*
Serial No. : 10/617,847
Conf. No. : 7988
Filed : July 10, 2003
For : New Therapeutic Use of 4-(2-Fluorophenyl)-6- Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

RESPONSE UNDER 37 CFR 1.111

Sir:

A Petition and Fee for a three-month Extension of Time accompany this paper.

In response to the Office Action dated July 13, 2006, the following remarks are respectfully presented.

Remarks/Arguments follow the amendment sections of this paper.

J:\gje\6757c1\Amend.doc\DNB\la